Low-Dose Naltrexone After Bariatric Surgery: What You Need to Know

How bariatric surgery affects drug absorption

Absorption after bariatric surgery is drug-specific rather than uniform. A systematic review of 26 studies (case reports, case series and non-randomized controlled studies) found evidence of reduced absorption for some medicines and not others, with most of the signals in jejunoileal bypass studies. The most consistent evidence was for cyclosporine, thyroxine, phenytoin and rifampin. The authors noted that poorly absorbed, highly lipophilic drugs and those that recirculate through the liver and gut carry the greatest potential for malabsorption, and that individual dose adjustment and monitoring may be required [2].

Oral naltrexone is well absorbed but undergoes significant first-pass metabolism. Its oral bioavailability is about 5% to 40%, peak levels of naltrexone and 6-beta-naltrexol occur within 1 hour, mean half-lives are about 4 hours for naltrexone and 13 hours for 6-beta-naltrexol, and excretion is mainly in urine [1].

The labels' opioid contraindication has no dose exception

The 50 mg tablet label and the Vivitrol 380 mg injection label contraindicate naltrexone in patients receiving opioid analgesics, patients currently dependent on opioids including those maintained on methadone or buprenorphine, anyone in acute opioid withdrawal, and anyone with a positive urine screen for opioids [1][3]. Neither label writes a dose exception for low-dose naltrexone [1][3].

The labels warn that starting naltrexone in someone who is opioid-dependent can precipitate severe withdrawal. In the tablet label, withdrawal symptoms usually appeared within five minutes of ingestion and lasted up to 48 hours, with mental status changes such as confusion, somnolence and visual hallucinations, fluid losses needing intravenous fluids, and postmarketing cases that required hospital admission and sometimes intensive care [1]. To avoid this, the labels recommend an opioid-free interval of at least 7 to 10 days, and note that people switching from buprenorphine or methadone may remain vulnerable to precipitated withdrawal for as long as 2 weeks [1][3].

If opioid pain relief is needed during treatment, the tablet label says the amount of opioid required may be greater than usual and the resulting respiratory depression may be deeper and more prolonged [1], while the Vivitrol label suggests regional analgesia or non-opioid analgesics [3]. Tolerance is lower at the end of a dosing interval, after a missed dose and after treatment stops, and fatal overdoses have been reported in people who used previously tolerated doses. Both labels advise strongly considering a naloxone or nalmefene rescue product when starting and renewing treatment [1][3].

What the LDN trials actually show

A small crossover study of 31 women with fibromyalgia reported pain falling 28.8% on 4.5 mg daily versus 18.0% on placebo (P=0.016) [6]. Later, larger placebo-controlled trials did not repeat that result. In 99 women taking 6 mg daily, the between-group pain difference was -0.34 points (95% CI -0.95 to 0.27, p=0.27) [7]. A 58-patient crossover found a median difference in FIQR score of -1.65 (P=0.3), and its authors concluded the data did not indicate any clinically relevant analgesic efficacy [9]. The 12-month INNOVA trial of 98 women found pain change of -0.33 points on LDN versus -0.64 on placebo at three months (p=0.236) [8]. A meta-analysis of 4 trials and 222 patients found a small pain difference (mean difference -0.86, 95% CI -1.20 to -0.51) but no significant difference in FIQR score [10]. A 2026 review of 105 studies, 15 of them randomized trials, concluded that early positive findings were rarely confirmed in placebo-controlled trials and that current evidence does not support routine clinical use [4]. The proposed TLR4 and microglial mechanisms remain largely theoretical [4].

Compounded LDN and what the labels list

LDN is not an FDA-approved product or indication; it is used off-label at 0.5 to 6 mg a day, most often 4.5 mg, a dose a 2026 review calls empirically derived rather than evidence-based [4]. FDA states that compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before they are marketed [5]. Naltrexone is not named on FDA's list of bulk drug substances that may present significant safety risks [11].

Neither current naltrexone label carries a boxed warning [1][3]. Hepatitis and clinically significant liver dysfunction appear in the warnings sections, and the Vivitrol label says to discontinue for symptoms or signs of acute hepatitis [3]. The tablet label says hepatocellular injury occurred in a substantial proportion of patients at doses up to 300 mg a day, five times the recommended dose [1]. Depression, suicidal ideation and suicide attempts have been reported after marketing, and the tablet label says no causal relationship has been demonstrated [1]. In an open-label safety study of about 570 people with alcoholism taking the tablet, new-onset nausea occurred in 10%, headache 7%, dizziness 4% and insomnia 3% [1]. LDN trials most often report insomnia, vivid dreams, nausea and dizziness, mostly mild and transient [4][10].

Contrave, a separate approved extended-release tablet containing naltrexone plus bupropion for weight management, carries a boxed warning for suicidal thoughts and behaviors, and its label says coadministration with other naltrexone-containing products is not recommended [12].